NewAmsterdam Pharma Company NV has published a document detailing the safety and efficacy of obicetrapib in patients at high cardiovascular risk. The document includes information on a study involving 2530 adult participants with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease. Key findings include the placebo-adjusted reduction in LDL-C with obicetrapib, which was 32.6% at day 84 and 24.0% at day 365. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.